Results for tag: "Liposomal Doxorubicin"

Liposomal Doxorubicin, a formulation of the chemotherapy drug doxorubicin, is part of a broader class of oncology drugs known as anthracyclines. This formulation encapsulates doxorubicin within liposomes, which are small, spherical vesicles composed of cholesterol and phospholipids. The liposomal encapsulation is designed to increase the drug's circulation time in the bloodstream, reduce the systemic toxicity traditionally associated with doxorubicin, and improve the targeting of the drug to cancerous tissues. This characteristic offers potential benefits in the treatment of various cancers, such as ovarian cancer, multiple myeloma, and Kaposi's sarcoma, especially in patients with HIV. Liposomal doxorubicin has been explored in numerous clinical trials and is employed in conjunction with other treatments to enhance therapeutic outcomes while trying to minimize adverse effects. Several companies are active in the liposomal doxorubicin market, contributing to its competitiveness and diversity. Notable players include Johnson & Johnson, through its subsidiary Janssen Products, which markets the drug under the name Doxil® in the United States. Other key companies involved in the production or distribution of liposomal doxorubicin include Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Pfizer, each offering generic or branded versions of the drug to meet the varying needs of oncology patients. These companies focus on research and development, production, and commercialization within the oncologic pharmaceutical sector. Show Less Read more